Key Points Viking Therapeutics' stock was volatile in 2025 due to clinical trial results. VK2735's oral form faced safety concerns but remains promising. Viking could be an acquisition target given its cash and drug pipeline. 10 stocks we like better than Viking Therapeutics › Investors in biotechnology company Viking Therapeutics (NASDAQ: VKTX) had a rollercoaster ride in 2025, driven by clinical trial data, or rather, the perception of the clinical trial data. Let's take a brief look at what hap ...